Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression

Journal of Experimental Medicine

Volumn 209, Issue 2, 2012, Pages 275-289

  Schulz, Ramona ^a   Marchenko, Natalia D ^b   Holembowski, Lena ^a   Fingerle Rowson, Günter ^c   Pesic, Marina ^d   Zender, Lars ^d,e   Dobbelstein, Matthias ^a   Moll, Ute M ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b STONY BROOK UNIVERSITY   (United States)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORKHEAD TRANSCRIPTION FACTOR; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; HISTONE DEACETYLASE 6; MACROPHAGE MIGRATION INHIBITION FACTOR; PROTEASOME; PROTEIN BAD; PROTEIN P53; SMALL INTERFERING RNA; TANESPIMYCIN; UBIQUITIN PROTEIN LIGASE E3;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BENZOQUINONES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DENSITOMETRY; DNA PRIMERS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LACTAMS, MACROCYCLIC; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; MICE, TRANSGENIC; MULTIPROTEIN COMPLEXES; PROTEIN STABILITY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING; UBIQUITIN-PROTEIN LIGASES;

EID: 84856821109     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20111117     Document Type: Article

References (76)

1. Bali, P., M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, et al. 2005. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280: 26729-26734. http://dx.doi.org/10.1074/jbc.C500186200
2. Bando, H., G. Matsumoto, M. Bando, M. Muta, T. Ogawa, N. Funata, J. Nishihira, M. Koike, and M. Toi. 2002. Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn. J. Cancer Res. 93: 389-396. http://dx.doi.org/10.1111/j.1349-7006.2002.tb01269.x
3. Banerji, U., M. Walton, F. Raynaud, R. Grimshaw, L. Kelland, M. Valenti, I. Judson, and P. Workman. 2005. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin. Cancer Res. 11: 7023-7032. http://dx.doi.org/10.1158/1078-0432.CCR-05-0518
4. Barrington, R.E., M.A. Subler, E. Rands, C.A. Omer, P.J. Miller, J.E. Hundley, S.K. Koester, D.A. Troyer, D.J. Bearss, M.W. Conner, et al.1998. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol. 18: 85-92.
5. Basso, A.D., D.B. Solit, G. Chiosis, B. Giri, P. Tsichlis, and N. Rosen. 2002. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J. Biol. Chem. 277: 39858-39866. http://dx.doi.org/10.1074/jbc.M206322200
6. Bini, L., B. Magi, B. Marzocchi, F. Arcuri, S. Tripodi, M. Cintorino, J.C. Sanchez, S. Frutiger, G. Hughes, V. Pallini, et al.1997. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis. 18: 2832-2841. http://dx.doi.org/10.1002/elps.1150181519
7. Binsky, I., M. Haran, D. Starlets, Y. Gore, F. Lantner, N. Harpaz, L. Leng, D.M. Goldenberg, L. Shvidel, A. Berrebi, et al. 2007. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc. Natl. Acad. Sci. USA. 104: 13408-13413. http://dx.doi.org/10.1073/pnas.0701553104
8. Bucala, R., and S.C. Donnelly. 2007. Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity. 26: 281-285. http://dx.doi.org/10.1016/j.immuni.2007.03.005
9. Calandra, T., and T. Roger. 2003. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat. Rev. Immunol. 3: 791-800. http://dx.doi.org/10.1038/nri1200
10. Cardiff, R.D., M.R. Anver, B.A. Gusterson, L. Hennighausen, R.A. Jensen, M.J. Merino, S. Rehm, J. Russo, F.A. Tavassoli, L.M. Wakefield, et al. 2000. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene.19: 968-988. http://dx.doi.org/10.1038/sj.onc.1203277
11. Chen, G., P. Cao, and D.V. Goeddel. 2002. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol. Cell. 9: 401-410. http://dx.doi.org/10.1016/S1097-2765(02)00450-1
12. Cheng, R.J., W.G. Deng, C.B. Niu, Y.Y. Li, and Y. Fu. 2011. Expression of macrophage migration inhibitory factor and CD74 in cervical squamous cell carcinoma. Int. J. Gynecol. Cancer. 21: 1004-1012. http://dx.doi.org/10.1097/IGC.0b013e31821c45b7
13. Cludts, S., C. Decaestecker, B. Johnson, J. Lechien, X. Leroy, N. Kindt, H. Kaltner, S. André, H.J. Gabius, and S. Saussez. 2010. Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma. Anticancer Res. 30: 3313-3319.
14. Conroy, H., L. Mawhinney, and S.C. Donnelly. 2010. Inflammation and cancer: macrophage migration inhibitory factor (MIF)-the potential missing link. QJM. 103: 831-836. http://dx.doi.org/10.1093/qjmed/hcq148
15. de Candia, P., D.B. Solit, D. Giri, E. Brogi, P.M. Siegel, A.B. Olshen, W.J. Muller, N. Rosen, and R. Benezra. 2003. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc. Natl. Acad. Sci. USA. 100: 12337-12342. http://dx.doi.org/10.1073/pnas.2031337100
16. Ehrlich, E.S., T. Wang, K. Luo, Z. Xiao, A.M. Niewiadomska, T. Martinez, W. Xu, L. Neckers, and X.-F. Yu. 2009. Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase. Proc. Natl. Acad. Sci. USA. 106: 20330-20335. http://dx.doi.org/10.1073/pnas.0810571106
17. Eiseman, J.L., J. Lan, T.F. Lagattuta, D.R. Hamburger, E. Joseph, J.M. Covey, and M.J. Egorin. 2005. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother. Pharmacol. 55: 21-32. http://dx.doi.org/10.1007/s00280-004-0865-3
18. Fingerle-Rowson, G., O. Petrenko, C.N. Metz, T.G. Forsthuber, R.A. Mitchell, R. Huss, U. Moll, W. Müller, and R. Bucala. 2003. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc. Natl. Acad. Sci. USA. 100: 9354-9359. http://dx.doi.org/10.1073/pnas.1533295100
19. Fingerle-Rowson, G., D.R. Kaleswarapu, C. Schlander, N. Kabgani, T. Brocks, N. Reinart, R. Busch, A. Schütz, H. Lue, X. Du, et al. 2009. A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation. Mol. Cell. Biol. 29: 1922-1932. http://dx.doi.org/10.1128/MCB.01907-08
20. Gibbs, A., J. Schwartzman, V. Deng, and J. Alumkal. 2009. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc. Natl. Acad. Sci. USA. 106: 16663-16668. http://dx.doi.org/10.1073/pnas.0908908106
21. Hagemann, T., J. Wilson, H. Kulbe, N.F. Li, D.A. Leinster, K. Charles, F. Klemm, T. Pukrop, C. Binder, and F.R. Balkwill. 2005. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J. Immunol. 175: 1197-1205.
22. Hagemann, T., S.C. Robinson, R.G. Thompson, K. Charles, H. Kulbe, and F.R. Balkwill. 2007. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol. Cancer Ther. 6: 1993-2002. http://dx.doi.org/10.1158/1535-7163.MCT-07-0118
23. He, X.X., J. Yang, Y.W. Ding, W. Liu, Q.Y. Shen, and H.H.X. Xia. 2006. Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut. 55: 797-802. http://dx.doi.org/10.1136/gut.2005.078113
24. Hira, E., T. Ono, D.K. Dhar, O.N. El-Assal, Y. Hishikawa, A. Yamanoi, and N. Nagasue. 2005. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer. 103: 588-598. http://dx.doi.org/10.1002/cncr.20818
25. Holembowski, L., R. Schulz, F. Talos, A. Scheel, S. Wolff, M. Dobbelstein, and U.M. Moll. 2011. While p73 is essential, p63 is completely dispensable for the development of the central nervous system. Cell Cycle. 10: 680-689. http://dx.doi.org/10.4161/cc.10.4.14859
26. Kamal, A., L. Thao, J. Sensintaffar, L. Zhang, M.F. Boehm, L.C. Fritz, and F.J. Burrows. 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 425: 407-410. http://dx.doi.org/10.1038/nature01913
27. Kang, J., A. Kamal, F.J. Burrows, B.M. Evers, and D.H. Chung. 2006. Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors. Anticancer Res. 26(3A): 1903-1908.
28. Kovacs, J.J., P.J.M. Murphy, S. Gaillard, X. Zhao, J.-T. Wu, C.V. Nicchitta, M. Yoshida, D.O. Toft, W.B. Pratt, and T.-P. Yao. 2005. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell. 18: 601-607. http://dx.doi.org/10.1016/j.molcel.2005.04.021
29. Lin, E.Y., J.F. Li, L. Gnatovskiy, Y. Deng, L. Zhu, D.A. Grzesik, H. Qian, X.N. Xue, and J.W. Pollard. 2006. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 66: 11238- 11246. http://dx.doi.org/10.1158/0008-5472.CAN-06-1278
30. Lubetsky, J.B., A. Dios, J. Han, B. Aljabari, B. Ruzsicska, R. Mitchell, E. Lolis, and Y. Al-Abed. 2002. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel antiinflammatory agents. J. Biol. Chem. 277: 24976-24982. http://dx.doi.org/10.1074/jbc.M203220200
31. Lue, H., M. Thiele, J. Franz, E. Dahl, S. Speckgens, L. Leng, G. Fingerle-Rowson, R. Bucala, B. Lüscher, and J. Bernhagen. 2007. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 26: 5046-5059. http://dx.doi.org/10.1038/sj.onc.1210318
32. Lugrin, J., X.C. Ding, D. Le Roy, A.-L. Chanson, F.C.G.J. Sweep, T. Calandra, and T. Roger. 2009. Histone deacetylase inhibitors repress macrophage migration inhibitory factor (MIF) expression by targeting MIF gene transcription through a local chromatin deacetylation. Biochim. Biophys. Acta. 1793: 1749-1758. http://dx.doi.org/10.1016/j.bbamcr.2009.09.007
33. Martin, J., F.J. Duncan, T. Keiser, S. Shin, D.F. Kusewitt, T. Oberyszyn, A.R. Satoskar, and A.M. VanBuskirk. 2009. Macrophage migration inhibitory factor (MIF) plays a critical role in pathogenesis of ultraviolet-B (UVB) -induced nonmelanoma skin cancer (NMSC). FASEB J. 23: 720-730. http://dx.doi.org/10.1096/fj.08-119628
34. Meyer-Siegler, K.L. 2000. Increased stability of macrophage migration inhibitory factor (MIF) in DU-145 prostate cancer cells. J. Interferon Cytokine Res. 20: 769-778. http://dx.doi.org/10.1089/10799900050151030
35. Meyer-Siegler, K.L., K.A. Iczkowski, L. Leng, R. Bucala, and P.L. Vera. 2006. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J. Immunol. 177: 8730-8739.
36. Meyer-Siegler, K.L., P.L. Vera, K.A. Iczkowski, C. Bifulco, A. Lee, P.K. Gregersen, L. Leng, and R. Bucala. 2007. Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun. 8: 646-652. http://dx.doi.org/10.1038/sj.gene.6364427
37. Mimnaugh, E.G., C. Chavany, and L. Neckers.1996. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor proteintyrosine kinase induced by geldanamycin. J. Biol. Chem. 271: 22796- 22801. http://dx.doi.org/10.1074/jbc.271.37.22796
38. Mitchell, R.A. 2004. Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell. Signal. 16: 13-19. http://dx.doi.org/10.1016/j.cellsig.2003.07.002
39. Modi, S., A. Stopeck, H. Linden, D. Solit, S. Chandarlapaty, N. Rosen, G. D'Andrea, M. Dickler, M.E. Moynahan, S. Sugarman, et al. 2011. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 17: 5132-5139. http://dx.doi.org/10.1158/1078-0432.CCR-11-0072
40. Morishima, Y., A.M. Wang, Z. Yu, W.B. Pratt, Y. Osawa, and A.P. Lieberman. 2008. CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins. Hum. Mol. Genet. 17: 3942-3952. http://dx.doi.org/10.1093/hmg/ddn296
41. Moulick, K., J.H. Ahn, H. Zong, A. Rodina, L. Cerchietti, E.M. Gomes DaGama, E. Caldas-Lopes, K. Beebe, F. Perna, K. Hatzi, et al. 2011. Affinitybased proteomics reveal cancer-specific networks coordinated by Hsp90. Nat. Chem. Biol. 7: 818-826. http://dx.doi.org/10.1038/nchembio.670
42. Muller, W.J., E. Sinn, P.K. Pattengale, R. Wallace, and P. Leder.1988. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 54: 105-115. http://dx.doi.org/10.1016/0092-8674(88)90184-5
43. Nemajerova, A., U.M. Moll, O. Petrenko, and G. Fingerle-Rowson. 2007. Macrophage migration inhibitory factor coordinates DNA damage response with the proteasomal control of the cell cycle. Cell Cycle. 6: 1030-1034. http://dx.doi.org/10.4161/cc.6.9.4163
44. Oda, S., T. Oda, K. Nishi, S. Takabuchi, T. Wakamatsu, T. Tanaka, T. Adachi, K. Fukuda, G.L. Semenza, and K. Hirota. 2008. Macrophage migration inhibitory factor activates hypoxia-inducible factor in a p53-dependent manner. PLoS ONE. 3: e2215. http://dx.doi.org/10.1371/journal.pone.0002215
45. Park, M.A., G. Zhang, C. Mitchell, M. Rahmani, H. Hamed, M.P. Hagan, A. Yacoub, D.T. Curiel, P.B. Fisher, S. Grant, and P. Dent. 2008. Mitogenactivated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Mol. Cancer Ther. 7: 2633-2648. http://dx.doi.org/10.1158/1535-7163.MCT-08-0400
46. Peng, Y., L. Chen, C. Li, W. Lu, and J. Chen. 2001. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J. Biol. Chem. 276: 40583-40590. http://dx.doi.org/10.1074/jbc.M102817200
47. Petrenko, O., and U.M. Moll. 2005. Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol. Cell. 17: 225-236. http://dx.doi.org/10.1016/j.molcel.2004.11.052
48. Petrenko, O., G. Fingerle-Rowson, T. Peng, R.A. Mitchell, and C.N. Metz. 2003. Macrophage migration inhibitory factor deficiency is associated with altered cell growth and reduced susceptibility to Rasmediated transformation. J. Biol. Chem. 278: 11078-11085. http://dx.doi.org/10.1074/jbc.M211985200
49. Pyle, M.E., M. Korbonits, M. Gueorguiev, S. Jordan, B. Kola, D.G. Morris, A. Meinhardt, M.P. Powell, F.X. Claret, Q. Zhang, et al. 2003. Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei. J. Endocrinol. 176: 103-110. http://dx.doi.org/10.1677/joe.0.1760103
50. Rendon, B.E., T. Roger, I. Teneng, M. Zhao, Y. Al-Abed, T. Calandra, and R.A. Mitchell. 2007. Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J. Biol. Chem. 282: 29910-29918. http://dx.doi.org/10.1074/jbc.M704898200
51. Reome, J.B., J.C. Hylind, R.W. Dutton, and M.J. Dobrzanski. 2004. Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer. Clin. Immunol. 111: 69-81. http://dx.doi.org/10.1016/j.clim.2003.11.013
52. Roger, T., X.C. Ding, A.-L. Chanson, P. Renner, and T. Calandra. 2007. Regulation of constitutive and microbial pathogen-induced human macrophage migration inhibitory factor (MIF) gene expression. Eur. J. Immunol. 37: 3509-3521. http://dx.doi.org/10.1002/eji.200737357
53. Scroggins, B.T., K. Robzyk, D. Wang, M.G. Marcu, S. Tsutsumi, K. Beebe, R.J. Cotter, S. Felts, D. Toft, L. Karnitz, et al. 2007. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell. 25: 151-159. http://dx.doi.org/10.1016/j.molcel.2006.12.008
54. Shi, X., L. Leng, T. Wang, W. Wang, X. Du, J. Li, C. McDonald, Z. Chen, J.W. Murphy, E. Lolis, et al. 2006. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity. 25: 595-606. http://dx.doi.org/10.1016/j.immuni.2006.08.020
55. Solit, D.B., F.F. Zheng, M. Drobnjak, P.N. Münster, B. Higgins, D. Verbel, G. Heller, W. Tong, C. Cordon-Cardo, D.B. Agus, et al. 2002. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 8: 986-993.
56. Sreedhar, A.S., E. Kalmár, P. Csermely, and Y.-F. Shen. 2004. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 562: 11-15. http://dx.doi.org/10.1016/S0014-5793(04)00229-7
57. Sun, J., L. Liu, X. Jiang, D. Chen, and Y. Huang. 2010. Therapeutic effects of radiolabeled 17-allylamino-17-demethoxygeldanamycin on human H460 nonsmall-cell lung carcinoma xenografts in mice. Cancer Biother. Radiopharm. 25: 155-164. http://dx.doi.org/10.1089/cbr.2009.0664
58. Taipale, M., D.F. Jarosz, and S. Lindquist. 2010. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 11: 515-528. http://dx.doi.org/10.1038/nrm2918
59. Talos, F., P. Mena, G. Fingerle-Rowson, U.M. Moll, and O. Petrenko. 2005. MIF loss impairs Myc-induced lymphomagenesis. Cell Death Differ. 12: 1319-1328. http://dx.doi.org/10.1038/sj.cdd.4401653
60. Taneja, P., D. Maglic, F. Kai, T. Sugiyama, R.D. Kendig, D.P. Frazier, M.C. Willingham, and K. Inoue. 2010. Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development. Cancer Res. 70: 9084-9094. http://dx.doi.org/10.1158/0008-5472.CAN-10-0159
61. Taylor, J.A. III, G.A. Kuchel, P. Hegde, O.S. Voznesensky, K. Claffey, J. Tsimikas, L. Leng, R. Bucala, and C. Pilbeam. 2007. Null mutation for macrophage migration inhibitory factor (MIF) is associated with less aggressive bladder cancer in mice. BMC Cancer. 7: 135. http://dx.doi.org/10.1186/1471-2407-7-135
62. Tomiyasu, M., I. Yoshino, R. Suemitsu, T. Okamoto, and K. Sugimachi. 2002. Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance. Clin. Cancer Res. 8: 3755-3760.
63. Trepel, J., M. Mollapour, G. Giaccone, and L. Neckers. 2010. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer. 10: 537-549. http://dx.doi.org/10.1038/nrc2887
64. Verjans, E., E. Noetzel, N. Bektas, A.K. Schütz, H. Lue, B. Lennartz, A. Hartmann, E. Dahl, and J. Bernhagen. 2009. Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer. 9: 230. http://dx.doi.org/10.1186/1471-2407-9-230
65. Wang, X.B., X.Y. Tian, Y. Li, B. Li, and Z. Li. 2012. Elevated expression of macrophage migration inhibitory factor correlates with tumor recurrence and poor prognosis of patients with gliomas. J. Neurooncol. 106: 43-51. http://dx.doi.org/10.1007/s11060-011-0640-3
66. Watanabe, G., K.E. Behrns, J.-S. Kim, and R.D. Kim. 2009. Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis. Cancer Chemother. Pharmacol. 64: 433-443. http://dx.doi.org/10.1007/s00280-008-0888-2
67. Welford, S.M., B. Bedogni, K. Gradin, L. Poellinger, M. Broome Powell, and A.J. Giaccia. 2006. HIF1alpha delays premature senescence through the activation of MIF. Genes Dev. 20: 3366-3371. http://dx.doi.org/10.1101/gad.1471106
68. Whitesell, L., and S.L. Lindquist. 2005. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer. 5: 761-772. http://dx.doi.org/10.1038/nrc1716
69. Whitesell, L., E.G. Mimnaugh, B. De Costa, C.E. Myers, and L.M. Neckers.1994. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA. 91: 8324-8328. http://dx.doi.org/10.1073/pnas.91.18.8324
70. Williams, C.R., R. Tabios, W.M. Linehan, and L. Neckers. 2007. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J. Urol. 178: 1528-1532. http://dx.doi.org/10.1016/j.juro.2007.05.120
71. Wilson, J.M., P.L. Coletta, R.J. Cuthbert, N. Scott, K. MacLennan, G. Hawcroft, L. Leng, J.B. Lubetsky, K.K. Jin, E. Lolis, et al. 2005. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology. 129: 1485-1503. http://dx.doi.org/10.1053/j.gastro.2005.07.061
72. Winner, M., A.C. Koong, B.E. Rendon, W. Zundel, and R.A. Mitchell. 2007. Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res. 67: 186-193. http://dx.doi.org/10.1158/0008-5472.CAN-06-3292
73. Xiao, X., X. Zuo, A.A. Davis, D.R. McMillan, B.B. Curry, J.A. Richardson, and I.J. Benjamin.1999. HSF1 is required for extra-embryonic development, postnatal growth and protection during inflammatory responses in mice. EMBO J. 18: 5943-5952. http://dx.doi.org/10.1093/emboj/18.21.5943
74. Xu, W., M. Marcu, X. Yuan, E. Mimnaugh, C. Patterson, and L. Neckers. 2002. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc. Natl. Acad. Sci. USA. 99: 12847- 12852. http://dx.doi.org/10.1073/pnas.202365899
75. Xu, X., B. Wang, C. Ye, C. Yao, Y. Lin, X. Huang, Y. Zhang, and S. Wang. 2008. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett. 261: 147-157. http://dx.doi.org/10.1016/j.canlet.2007.11.028
76. Zhang, C., T. Liang, J. Song, S. Jiang, L. Qu, and G. Hou. 2011. Evaluation of macrophage migration inhibitory factor as an imaging marker for hepatocellular carcinoma in murine models. Scand. J. Gastroenterol. 46: 720-726. http://dx.doi.org/10.3109/00365521.2011.568517